Related Experiment Video
Updated: Jun 19, 2026
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung
Howard West1, David Harpole2, William Travis3
1Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA.
Abstract:
Over the past 5 to 10 years, we have reached a treatment plateau using standard platinum-based doublets in an unselected population of patients with advanced non-small cell lung cancer (NSCLC). Recent studies have focused on improving patient outcomes with new chemotherapeutic or targeted agents, as well as on individualizing therapy on the basis of patient characteristics such as tumor histology and biomarker analysis. This article summarizes recent data on histologic response determinants to chemotherapy and targeted therapy, with particular attention to the importance of standardized tissue collection, handling, storage, and analysis techniques, in order to best apply the results of tumor analysis to patient-care decisions. Such decisions are related to both improving patient safety and optimizing efficacy with standard chemotherapy as well as newer targeted therapy agents. This entails a change from a generalized approach in treating patients with NSCLC to an individualized strategy based on tumor histology.
Insights
Standard platinum-based chemotherapy shows limited efficacy in advanced non-small cell lung cancer (NSCLC). Individualizing treatment based on tumor histology and biomarkers is crucial for improving patient outcomes and optimizing therapy.
Area of Science:
- Oncology
- Pulmonology
- Medical Diagnostics
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment has plateaued with standard platinum-based chemotherapy.
- There is a growing need for personalized treatment strategies in NSCLC.
Purpose of the Study:
- To summarize recent data on histologic determinants of response to chemotherapy and targeted therapy in NSCLC.
- To emphasize the importance of standardized tissue handling for accurate biomarker analysis and patient care.
Main Methods:
- Review of recent studies on histologic response in NSCLC.
- Discussion of standardized tissue collection, handling, storage, and analysis techniques.
Main Results:
- Tumor histology and biomarker analysis are key factors in determining treatment response.
- Standardized tissue processing is essential for reliable diagnostic results.
Conclusions:
- Individualized treatment strategies based on tumor histology improve patient safety and efficacy in NSCLC.
- A shift from generalized to personalized therapy is necessary for optimal NSCLC management.
